Imfinzi加上卡介苗将高危膀胱癌患者的复发/死亡减少32%,与Tecentriq不同,后者增加了副作用而无益。 Imfinzi plus BCG reduced recurrence/death by 32% in high-risk bladder cancer patients, unlike Tecentriq, which increased side effects without benefit.

在2025年ESMO大会上提出的第3阶段试验发现,将Imfinzi(durvalumab)添加到上岗治疗和维持治疗Bacillus Calmette-Guérin(BCG)中,大大改善了高风险、BCG-naïve非肌肉侵入性膀胱癌患者的无疾病生存,仅与BCG相比,复发或死亡风险就减少了32%。 A phase 3 trial presented at the 2025 ESMO Congress found that adding Imfinzi (durvalumab) to both induction and maintenance Bacillus Calmette–Guérin (BCG) therapy significantly improved disease-free survival in high-risk, BCG-naïve non-muscle-invasive bladder cancer patients, reducing recurrence or death risk by 32% compared to BCG alone. 当Imfinzi只是在上岗时才被使用时,没有看到这项福利。 The benefit was not seen when Imfinzi was used only during induction. 药物组合耐受性良好,副作用可控,包括失尿和血,并没有恶化生活质量. The combination was well-tolerated with manageable side effects, including dysuria and hematuria, and did not worsen quality of life. 与此相反,在卡介苗中增加Tecentriq(atezolizumab)没有改善类似组别的结果,导致更频繁和严重的不良事件,包括停止治疗的比率较高。 In contrast, adding Tecentriq (atezolizumab) to BCG did not improve outcomes in a similar group and led to more frequent and severe adverse events, including higher rates of treatment discontinuation. 这些调查结果表明,Imfinzi加卡介苗可能是一种有希望的新治疗方案,而Tecentriq的添加并没有带来好处和增加毒性。 These findings suggest Imfinzi plus BCG may be a promising new treatment option, while Tecentriq’s addition did not provide benefit and increased toxicity.